Related Experiment Video
Updated: May 23, 2025
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
997
Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in
Takuma Yoshimura1, Kohei Nakamura2, Tatsuyuki Chiyoda3
1Department of Obstetrics and Gynecology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
BJC Reports
|May 20, 2025
Summary
Next-generation sequencing (NGS) offers superior molecular classification for endometrial cancer (EC) compared to ProMisE, enabling better patient stratification and prognostication for personalized treatment.
Area of Science:
- Oncology
- Genomics
- Molecular Pathology
Background:
- Endometrial cancer (EC) classification relies on molecular subtypes.
- Accurate classification is crucial for prognostication and treatment selection.
Purpose of the Study:
- To compare the efficacy of next-generation sequencing (NGS) and Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in molecularly classifying EC.
- To evaluate the prognostic value of NGS-based molecular subtypes.
Main Methods:
- Analyzed 200 EC cases using cancer gene panel testing for 145 genes.
- Classified tumors into POLE, microsatellite instability-high (MSI-H), copy number low (CN-L), and copy number high (CN-H) subtypes.
- Assessed p53 and mismatch repair gene status via immunohistochemistry.
Main Results:
- NGS identified CN-L as the most frequent subtype (52.0%), followed by MSI-H (19.0%), POLE (16.5%), and CN-H (12.5%).
- NGS-based classification showed a significant difference in overall survival (p=0.006), unlike ProMisE (p=0.117).
- Identified additional mutations in POLE subtypes and found no significant prognostic difference based on p53 status in CN-H cases.
Conclusions:
- NGS provides more precise molecular stratification and prognostication for EC than ProMisE.
- The developed NGS platform has potential for guiding personalized treatment strategies in EC.
